Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606502 · ClinicalTrials.gov registry record · Phase 2
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT00606502 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 201 participants.
The verdict
NCT00606502, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Interventions
- DIETARY_SUPPLEMENT Vitamin B12
- DRUG Pralatrexate
- DRUG Erlotinib
- DIETARY_SUPPLEMENT Folic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606502
The ClinicalTrials.gov registry entry for NCT00606502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vitamin B12 is the first listed.
NCT00606502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606502 about?
NCT00606502 is a clinical study titled "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment". The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received a...
What is the current status of trial NCT00606502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2008-01. Estimated completion is 2010-06-24.
What interventions are being tested in trial NCT00606502?
The interventions under investigation include: Vitamin B12 (DIETARY_SUPPLEMENT), Pralatrexate (DRUG), Erlotinib (DRUG), Folic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00606502?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.